Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

436
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
436
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

289
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
289
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

540
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

593
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
593
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

402
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
402
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The burden of steroid use in systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

Interdisciplinary Clinical Practice Guidelines for patient-centred management of juvenile-onset systemic lupus erythematosus.

EULAR rheumatology open·2026
Same author

Belimumab induces early and sustained resolution of lupus thrombocytopenia.

Lupus science & medicine·2026
Same author

Zeitschrift fur Rheumatologie·2026
Same author

Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database.

Journal of autoimmunity·2026
Same author

[Proposal of the rheumatology societies in the D-A-CH region for a uniform German nomenclature for Sjögren's disease].

Zeitschrift fur Rheumatologie·2026
Same journal

The Outcome of Cardiac Hydatid Surgery in The Iraqi Center of Heart Diseases.

F1000Research·2026
Same journal

Perception of body donation among the Phase-1 medical students, a questionnaire-based study.

F1000Research·2026
Same journal

Exploring Infertility in Saudi Arabia: Qualitative Insights into IVF Treatment Services and Policy Recommendations.

F1000Research·2026
Same journal

Cyber Military Operations under International Humanitarian Law: Interpreting the Concept of "Attack" and Challenges in Protecting Civilians.

F1000Research·2026
Same journal

Sentiment Analysis of Acceptance TVET Online Courses on the Skill Academy App from Google Play: Leveraging Text Mining with Comparison Machine Learning Model.

F1000Research·2026
Same journal

Emotional intelligence: An important skill to learn now more than ever.

F1000Research·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.0K

Recent advances in managing systemic sclerosis.

Martin Aringer1, Anne Erler1

  • 1Division of Rheumatology, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus at the TU Dresden, Dresden, Germany.

F1000Research
|February 11, 2017
PubMed
Summary
This summary is machine-generated.

Systemic sclerosis involves autoimmunity, vasculopathy, and fibrosis. While vascular treatments are established and immunomodulatory evidence grows, new anti-fibrosis drugs offer hope for future therapies.

Keywords:
ACE inhibitorsSScphosphodiesterase 5 blockerssclerodermasystemic sclerosis

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.7K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 7, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.0K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.7K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K

Area of Science:

  • Rheumatology and immunology
  • Vascular biology
  • Fibrosis research

Background:

  • Systemic sclerosis pathogenesis involves complex interactions between autoimmunity, vasculopathy, and fibrosis.
  • Understanding the interplay of these components is crucial for developing effective treatments.
  • Current therapeutic strategies target individual components with varying success.

Purpose of the Study:

  • To review the current understanding of how autoimmunity, vasculopathy, and fibrosis interact in systemic sclerosis.
  • To evaluate the established and emerging treatment options for each component.
  • To provide a hopeful outlook on future therapeutic advancements.

Main Methods:

  • Literature review of studies on systemic sclerosis pathogenesis.
  • Analysis of clinical trial data for immunomodulatory and anti-fibrosis therapies.
  • Synthesis of evidence regarding the efficacy of current vascular treatments.

Main Results:

  • Vascular treatment options for systemic sclerosis are well-established.
  • Evidence supporting the efficacy of immunomodulatory approaches is growing.
  • Promising anti-fibrosis substances are currently under investigation.

Conclusions:

  • While the precise integration of autoimmunity, vasculopathy, and fibrosis in systemic sclerosis remains unclear, significant therapeutic progress is being made.
  • Established vascular treatments, increasing evidence for immunomodulation, and novel anti-fibrosis agents offer hope for improved patient outcomes.
  • Future breakthroughs in understanding and treating systemic sclerosis are anticipated.